Clinical Trials Logo

Skin Neoplasms clinical trials

View clinical trials related to Skin Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06274905 Completed - Clinical trials for Head and Neck Cancer

Topical Anaesthesia in Cutaneous Head and Neck Surgery

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

This study aims to assess if EMLA or ethyl chloride spray are effective in reducing the pain associated with local anaesthetic administration in cutaneous surgery of the head and neck compared to a placebo and control group through a randomized control trial study design.

NCT ID: NCT06152367 Completed - Clinical trials for Stage IV Malignant Melanoma of Skin

Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

Start date: January 30, 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery methods, radiotherapy, or conventional available chemotherapy. The disseminated tumor is refractory to all standard treatments. Almost 100% of patients who develop distant metastases will die from their disease, either from complications or cachexia. Therefore, immunotherapy based on immunological stimulation with immunocompetent dendritic cells, added to immunological reinforcement with IL-2, can, according to the evidence emanating from ongoing clinical protocols, produce a prolongation of survival with better quality and, in some cases, with partial or total regression of the tumor. General objective: It is to study the clinical and immunological response of patients treated with vaccines based on autologous dendritic cells loaded with tumor antigens, derived from allogeneic melanoma extracts, in combination or not, with intercalated low doses of recombinant human interleukin 2 (rhIL2) PROLEUKIN ® (aldesleukin). MAIN SPECIFIC OBJECTIVE: - SAFETY: Safety in administering dendritic cell preparation; local and systemic toxicity estimation. Determination of adverse reactions such as fever, nausea, allergy, neurological and cardiovascular symptoms. Local toxicity in the administration area. - MEASUREMENT OF THE IMMUNE RESPONSE: Based on in vivo and in vitro parameters: - In vivo response: Measure the type IV Delayed Hypersensitivity (DTH) response. It consists of a crossover test in which the response is compared to tissue interaction in vivo between dendritic cells sensitized with tumor extracts and their respective control unloaded dendritic cells. - In vitro response: ELISPOT assays, measurement of IFN-γ gamma production in peripheral blood of treated patients. Compare the specific immune response after each cycle of therapy through measurement of IFN-γ production by tumor-specific CTL. Cytotoxic radioactive chromium release assays to measure anti-tumor response mediated by CTL and NK. ELISA assays for quantifying cytokines (IFN-γ, IL-10) in patient serum after each cycle of therapy.

NCT ID: NCT05842421 Completed - Clinical trials for Non-melanoma Skin Cancer

Imaging Methods for the Diagnosis of Non-melanoma Skin Cancer and Its Precursors

Start date: April 21, 2021
Phase: N/A
Study type: Interventional

Prospective, unicentric study that examines if imaging devices like total body photography, dermoscopy, optical coherence tomography and in vivo reflectance confocal microscopy as an addition to clinical examination lead to a benefit for patients in the diagnosis of non-melanoma skin cancer and their precursors

NCT ID: NCT05788939 Completed - Skin Neoplasm Clinical Trials

PLANNED VISUAL EDUCATION ABOUT SKIN CANCER

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This study aimed to evaluate the effect of planned visual education based on the Health Belief Model on university students' attitudes and beliefs toward skin cancer. The planned visual education based in Health Belief Model has possitive effects on univestiy students' attitudes and beliefs toward skin cancer.

NCT ID: NCT05736224 Completed - Skin Cancer Clinical Trials

Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen

Start date: May 15, 2023
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the effects of a novel sunscreen formulation by assessing the extent of ultraviolet radiation (UVR)-induced direct and indirect cellular and DNA damage to human skin, in the presence vs absence of the sunscreen, in a population of healthy adults with fair skin (Fitzpatrick Scale type I, II or III).

NCT ID: NCT05661370 Completed - Melanoma (Skin) Clinical Trials

App Teaches Doctors to Diagnose Skin Cancer

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

This study aimed to examine if self-paced learning with a novel digital patient-case-based educational platform can increase primary care physicians' diagnostic accuracy of malignant and benign skin lesions on both the level of benign/malignant and the diagnosis level. Secondarily the study aimed to investigate the time spent in reaching this change in proficiency.

NCT ID: NCT05389085 Completed - Malignant Melanoma Clinical Trials

Fast Track Diagnosis of Skin Cancer by Advanced Imaging Technologies and Tumour Tapestripping

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

In this clinical feasibility study the investigators will test and compare two advanced optical imaging technologies, lipid and RNA tape stripping with regards to diagnostic accuracies for fast bedside diagnosis of pigmented skin tumours.

NCT ID: NCT05315128 Completed - Clinical trials for Non-melanoma Skin Cancers

Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers

Start date: July 6, 2020
Phase: Phase 2
Study type: Interventional

to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management

NCT ID: NCT05146622 Completed - Skin Cancer Clinical Trials

Virtual Sun Safe Workplaces Ph I

SSW Works
Start date: October 28, 2021
Phase:
Study type: Observational

Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation over a lifetime that substantially increases their risk for developing skin cancer. In Phase I, the feasibility of a virtual learning environment (VLE) for distributing our effective Sun Safe Workplaces (SSW) intervention to American employers will be established with input from senior managers and Hispanic and African American outdoor workers and development and evaluation of a prototype of the SSW Works VLE. In Phase II, the full SSW Works will be produced and tested for effectiveness at improving outdoor workers' sun protection in a randomized trial enrolling employers nationwide.

NCT ID: NCT05102773 Completed - Clinical trials for Clinical Stage IV Cutaneous Melanoma AJCC v8

The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients

Start date: February 10, 2020
Phase:
Study type: Observational

This pilot trial studies the effect of the microbiome on immune checkpoint inhibitors response in patients with melanoma by collecting stool and blood samples. Gut microbiome plays a critical role in response to immune checkpoint inhibitors. Studying the change in an individual's microbiome due to corticosteroid use may help researchers to determine whether an individual's microbiome can predict their response and toxicity to immune checkpoint inhibitors.